Key Points
- Matthew Winton purchased a total of 15,000 CervoMed shares across Nov 14–18 (10,000 at $7.57, 3,500 at $8.43 and 1,500 at $7.95), boosting his direct stake by 11.11% to 15,000 shares.
- Shares rose about 4.1% to $8.97 on light trading (34,856 shares vs. an average of ~1.48M), and the company has a market cap near $83 million with a one‑year range of $1.80–$16.94.
- CervoMed reported a Q with a ($0.84) EPS miss and $0.32M revenue (vs. $1.43M expected), but analysts remain broadly bullish with a consensus "Moderate Buy" and a target price of $21.86.
CervoMed Inc. (NASDAQ:CRVO - Get Free Report) insider Matthew Winton purchased 1,500 shares of CervoMed stock in a transaction that occurred on Tuesday, November 18th. The shares were bought at an average price of $7.95 per share, for a total transaction of $11,925.00. Following the transaction, the insider directly owned 15,000 shares of the company's stock, valued at $119,250. This trade represents a 11.11% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Matthew Winton also recently made the following trade(s):
- On Monday, November 17th, Matthew Winton acquired 3,500 shares of CervoMed stock. The stock was bought at an average price of $8.43 per share, with a total value of $29,505.00.
- On Friday, November 14th, Matthew Winton acquired 10,000 shares of CervoMed stock. The shares were purchased at an average cost of $7.57 per share, for a total transaction of $75,700.00.
CervoMed Trading Up 4.1%
Shares of CRVO stock traded up $0.36 during midday trading on Thursday, reaching $8.97. 34,856 shares of the stock were exchanged, compared to its average volume of 1,477,774. CervoMed Inc. has a 1 year low of $1.80 and a 1 year high of $16.94. The firm has a market cap of $82.95 million, a PE ratio of -3.43 and a beta of -0.89. The company's 50 day moving average is $7.79 and its two-hundred day moving average is $8.12.
CervoMed (NASDAQ:CRVO - Get Free Report) last released its earnings results on Friday, November 7th. The company reported ($0.84) EPS for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.16). The firm had revenue of $0.32 million during the quarter, compared to analysts' expectations of $1.43 million. CervoMed had a negative net margin of 290.72% and a negative return on equity of 59.15%. As a group, equities analysts expect that CervoMed Inc. will post -1.88 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
A number of analysts have recently commented on CRVO shares. Canaccord Genuity Group boosted their target price on shares of CervoMed from $21.00 to $27.00 and gave the company a "buy" rating in a report on Tuesday, July 29th. Roth Capital set a $20.00 price objective on shares of CervoMed and gave the stock a "buy" rating in a research note on Friday, October 17th. D. Boral Capital restated a "buy" rating and issued a $31.00 price objective on shares of CervoMed in a report on Tuesday, November 11th. HC Wainwright raised shares of CervoMed from a "neutral" rating to a "buy" rating and raised their target price for the company from $11.00 to $25.00 in a research note on Wednesday, November 5th. Finally, Chardan Capital reissued a "buy" rating and issued a $15.00 price target on shares of CervoMed in a research report on Monday, August 11th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and three have assigned a Sell rating to the company's stock. According to data from MarketBeat.com, CervoMed presently has a consensus rating of "Moderate Buy" and a consensus target price of $21.86.
Read Our Latest Stock Report on CervoMed
Institutional Trading of CervoMed
A number of institutional investors and hedge funds have recently bought and sold shares of the company. Rhumbline Advisers lifted its stake in shares of CervoMed by 35.5% in the first quarter. Rhumbline Advisers now owns 5,830 shares of the company's stock worth $53,000 after buying an additional 1,526 shares in the last quarter. Marshall Wace LLP purchased a new position in CervoMed in the 2nd quarter worth approximately $76,000. Thompson Davis & CO. Inc. bought a new position in CervoMed in the 2nd quarter valued at approximately $88,000. GSA Capital Partners LLP purchased a new stake in CervoMed during the 3rd quarter valued at $91,000. Finally, HighTower Advisors LLC bought a new stake in shares of CervoMed in the 1st quarter worth $104,000. 25.15% of the stock is currently owned by institutional investors.
About CervoMed
(
Get Free Report)
CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
